Advanced search
Publication Cover
OncoImmunology Volume 9, 2020 - Issue 1
Submit an article Journal homepage
2,882
Views
12
CrossRef citations to date
0
Altmetric
Research Article

ROS1-fusion protein induces PD-L1 expression via MEK-ERK activation in non-small cell lung cancer

Zheng Liua Department of Thoracic Surgery, West China Hospital, Sichuan University, Chengdu, Sichuan, China;b Western China Collaborative Innovation Center for Early Diagnosis and Multidisciplinary Therapy of Lung Cancer, Sichuan University, Chengdu 610041, ChinaView further author information
,
Kejia Zhaoa Department of Thoracic Surgery, West China Hospital, Sichuan University, Chengdu, Sichuan, China;b Western China Collaborative Innovation Center for Early Diagnosis and Multidisciplinary Therapy of Lung Cancer, Sichuan University, Chengdu 610041, ChinaView further author information
,
Shiyou Weia Department of Thoracic Surgery, West China Hospital, Sichuan University, Chengdu, Sichuan, China;b Western China Collaborative Innovation Center for Early Diagnosis and Multidisciplinary Therapy of Lung Cancer, Sichuan University, Chengdu 610041, ChinaView further author information
,
Chengwu Liua Department of Thoracic Surgery, West China Hospital, Sichuan University, Chengdu, Sichuan, China;b Western China Collaborative Innovation Center for Early Diagnosis and Multidisciplinary Therapy of Lung Cancer, Sichuan University, Chengdu 610041, ChinaView further author information
,
Jiankang Zhouc State Key Laboratory of Biotherapy/Collaborative Innovation Center for Biotherapy, West West China Hospital, Sichuan University, Chengdu, Sichuan, ChinaView further author information
,
Qiheng Gouc State Key Laboratory of Biotherapy/Collaborative Innovation Center for Biotherapy, West West China Hospital, Sichuan University, Chengdu, Sichuan, ChinaView further author information
,
Xia Wud Department of Pathology, West China Hospital, Sichuan University, Chengdu, Sichuan, ChinaView further author information
,
Zhenyu Yanga Department of Thoracic Surgery, West China Hospital, Sichuan University, Chengdu, Sichuan, China;b Western China Collaborative Innovation Center for Early Diagnosis and Multidisciplinary Therapy of Lung Cancer, Sichuan University, Chengdu 610041, ChinaView further author information
,
Yanbo Yanga Department of Thoracic Surgery, West China Hospital, Sichuan University, Chengdu, Sichuan, China;b Western China Collaborative Innovation Center for Early Diagnosis and Multidisciplinary Therapy of Lung Cancer, Sichuan University, Chengdu 610041, ChinaView further author information
,
Yong Penga Department of Thoracic Surgery, West China Hospital, Sichuan University, Chengdu, Sichuan, China;b Western China Collaborative Innovation Center for Early Diagnosis and Multidisciplinary Therapy of Lung Cancer, Sichuan University, Chengdu 610041, China;c State Key Laboratory of Biotherapy/Collaborative Innovation Center for Biotherapy, West West China Hospital, Sichuan University, Chengdu, Sichuan, ChinaView further author information
,
Qing Chenge Department of Surgery, Duke University School of Medicine, Durham, North Carolina, USAView further author information
&
Lunxu Liua Department of Thoracic Surgery, West China Hospital, Sichuan University, Chengdu, Sichuan, China;b Western China Collaborative Innovation Center for Early Diagnosis and Multidisciplinary Therapy of Lung Cancer, Sichuan University, Chengdu 610041, ChinaCorrespondence[email protected]
View further author information
 show all
Article: 1758003 | Received 15 Sep 2019, Accepted 30 Mar 2020, Published online: 06 May 2020

References

  • Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ, Topalian SL, Hwu P, Drake CG, Camacho LH, Kauh J, Odunsi K, et al. Safety and activity of anti-PD-l1 antibody in patients with advanced cancer. N Engl J Med. 2012;366(26):2455–9. doi:10.1056/NEJMoa1200694.
  • Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, Powderly JD, Carvajal RD, Sosman JA, Atkins MB, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012;366(26):2443–2454. doi:10.1056/NEJMoa1200690.
  • Borghaei H, Paz-Ares L, Horn L, Spigel D, Steins M, Ready N, Chow L, Vokes E, Felip E, Holgado E, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med. 2015;373(17):1627–1639. doi:10.1056/NEJMoa1507643.
  • Brahmer J, Reckamp K, Baas P, Crinò L, Eberhardt W, Poddubskaya E, Antonia S, Pluzanski A, Vokes E, Holgado E, et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med. 2015;373(2):123–135. doi:10.1056/NEJMoa1504627.
  • Rangachari D, VanderLaan PA, Shea M, Le X, Huberman MS, Kobayashi SS, Costa DB. Correlation between classic driver oncogene mutations in egfr, alk, or ros1 and 22c3-PD-l1 >/=50% expression in lung adenocarcinoma. J Thorac Oncol. 2017;12(5):878–883. doi:10.1016/j.jtho.2016.12.026.
  • Shien K, Papadimitrakopoulou VA, Wistuba II. Predictive biomarkers of response to PD-1/PD-l1 immune checkpoint inhibitors in non-small cell lung cancer. Lung Cancer. 2016;99:79–87. doi:10.1016/j.lungcan.2016.06.016.
  • Saigi M, Alburquerque-Bejar JJ, Mc Leer-Florin A, Pereira C, Pros E, Romero OA, Baixeras N, Esteve-Codina A, Nadal E, Brambilla E, et al. Met-oncogenic and jak2-inactivating alterations are independent factors that affect regulation of PD-l1 expression in lung cancer. Clin Cancer Res. 2018;24(18):4579–4587. doi:10.1158/1078-0432.Ccr-18-0267.
  • Azuma K, Ota K, Kawahara A, Hattori S, Iwama E, Harada T, Matsumoto K, Takayama K, Takamori S, Kage M, et al. Association of PD-l1 overexpression with activating EGFR mutations in surgically resected nonsmall-cell lung cancer. Ann Oncol. 2014;25(10):1935–1940. doi:10.1093/annonc/mdu242.
  • Lastwika KJ, Wilson W, Li QK, Norris J, Xu H, Ghazarian SR, Kitagawa H, Kawabata S, Taube JM, Yao S, et al. Control of PD-l1 expression by oncogenic activation of the AKT-mTOR pathway in non-small cell lung cancer. Cancer Res. 2016;76(2):227–238. doi:10.1158/0008-5472.Can-14-3362.
  • Takeuchi K, Soda M, Togashi Y, Suzuki R, Sakata S, Hatano S, Asaka R, Hamanaka W, Ninomiya H, Uehara H, et al. Ret, ros1 and alk fusions in lung cancer. Nat Med. 2012;18(3):378–381. doi:10.1038/nm.2658.
  • Bergethon K, Shaw AT, Ou SH, Katayama R, Lovly CM, McDonald NT, Massion PP, Siwak-Tapp C, Gonzalez A, Fang R, et al. Ros1 rearrangements define a unique molecular class of lung cancers. J Clin Oncol. 2012;30(8):863–870. doi:10.1200/JCO.2011.35.6345.
  • Davies KD, Doebele RC. Molecular pathways: ros1 fusion proteins in cancer. Clin Cancer Res. 2013;19(15):4040–4045. doi:10.1158/1078-0432.CCR-12-2851.
  • Jun HJ, Johnson H, Bronson RT, de Feraudy S, White F, Charest A. The oncogenic lung cancer fusion kinase cd74-ros activates a novel invasiveness pathway through e-syt1 phosphorylation. Cancer Res. 2012;72(15):3764–3774. doi:10.1158/0008-5472.CAN-11-3990.
  • Shaw AT, Hsu PP, Awad MM, Engelman JA. Tyrosine kinase gene rearrangements in epithelial malignancies. Nat Rev Cancer. 2013;13(11):772–787. doi:10.1038/nrc3612.
  • Coelho M, de Carné Trécesson S, Rana S, Zecchin D, Moore C, Molina-Arcas M, East P, Spencer-Dene B, Nye E, Barnouin K, et al. Oncogenic ras signaling promotes tumor immunoresistance by stabilizing pd-l1 mrna. Immunity. 2017;47(6):1083–1099.e1086. doi:10.1016/j.immuni.2017.11.016.
  • Lee J, Park CK, Yoon HK, Sa YJ, Woo IS, Kim HR, Kim SY, Kim TJ. Pd-l1 expression in ros1-rearranged non-small cell lung cancer: A study using simultaneous genotypic screening of egfr, alk, and ros1. Thoracic Cancer. 2019;10(1):103–110. doi:10.1111/1759-7714.12917.
  • Ogawa H, Tanaka Y, Tachihara M, Uehara K, Shimizu N, Doi T, Hokka D, Maniwa Y. Ros1-rearranged high-PD-l1-expressing lung adenocarcinoma manifesting as mediastinal tumor: A case report. Oncol Lett. 2019;17(1):488–491. doi:10.3892/ol.2018.9622.
  • Akbay EA, Koyama S, Carretero J, Altabef A, Tchaicha JH, Christensen CL, Mikse OR, Cherniack AD, Beauchamp EM, Pugh TJ, et al. Activation of the PD-1 pathway contributes to immune escape in egfr-driven lung tumors. Cancer Discov. 2013;3(12):1355–1363. doi:10.1158/2159-8290.CD-13-0310.
  • Hong S, Chen N, Fang W, Zhan J, Liu Q, Kang S, He X, Liu L, Zhou T, Huang J, et al. Upregulation of PD-l1 by EML4-ALK fusion protein mediates the immune escape in ALK positive NSCLC: implication for optional anti-PD-1/PD-l1 immune therapy for ALK-TKIs sensitive and resistant nsclc patients. Oncoimmunology. 2016;5(3):e1094598. doi:10.1080/2162402x.2015.1094598.
  • Koh J, Jang JY, Keam B, Kim S, Kim MY, Go H, Kim TM, Kim DW, Kim CW, Jeon YK, et al. Eml4-alk enhances programmed cell death-ligand 1 expression in pulmonary adenocarcinoma via hypoxia-inducible factor (HIF)-1alpha and stat3. Oncoimmunology. 2016;5(3):e1108514. doi:10.1080/2162402x.2015.1108514.
  • Chen N, Fang W, Zhan J, Hong S, Tang Y, Kang S, Zhang Y, He X, Zhou T, Qin T, et al. Upregulation of PD-l1 by egfr activation mediates the immune escape in egfr-driven nsclc: implication for optional immune targeted therapy for NSCLC patients with egfr mutation. J Thorac Oncol. 2015;10(6):910–923. doi:10.1097/jto.0000000000000500.
  • Ota K, Azuma K, Kawahara A, Hattori S, Iwama E, Tanizaki J, Harada T, Matsumoto K, Takayama K, Takamori S, et al. Induction of PD-l1 expression by the eml4-alk oncoprotein and downstream signaling pathways in non-small cell lung cancer. Clin Cancer Res. 2015;21(17):4014–4021. doi:10.1158/1078-0432.CCR-15-0016.
  • Davies KD, Le AT, Theodoro MF, Skokan MC, Aisner DL, Berge EM, Terracciano LM, Cappuzzo F, Incarbone M, Roncalli M, et al. Identifying and targeting ros1 gene fusions in non-small cell lung cancer. Clin Cancer Res. 2012;18(17):4570–4579. doi:10.1158/1078-0432.ccr-12-0550.
  • Song A, Kim T, Kim D, Kim S, Keam B, Lee S, Heo D. Molecular changes associated with acquired resistance to crizotinib in ros1-rearranged non-small cell lung cancer. Clin Cancer Res. 2015;21(10):2379–2387. doi:10.1158/1078-0432.CCR-14-1350.
  • Hanna N, Johnson D, Temin S, Baker S Jr., Brahmer J, Ellis PM, Giaccone G, Hesketh PJ, Jaiyesimi I, Leighl NB, et al. Systemic therapy for stage iv non-small-cell lung cancer: american society of clinical oncology clinical practice guideline update. J Clin Oncol. 2017;35(30):3484–3515. doi:10.1200/jco.2017.74.6065.
  • Shukuya T, Carbone DP. Predictive markers for the efficacy of anti-PD-1/PD-l1 antibodies in lung cancer. J Thorac Oncol. 2016;11(7):976–988. doi:10.1016/j.jtho.2016.02.015.
  • Chen N, Fang W, Lin Z, Peng P, Wang J, Zhan J, Hong S, Huang J, Liu L, Sheng J, et al. Kras mutation-induced upregulation of PD-l1 mediates immune escape in human lung adenocarcinoma. Cancer Immunol Immuno. 2017;66(9):1175–1187. doi:10.1007/s00262-017-2005-z.
  • Rikova K, Guo A, Zeng Q, Possemato A, Yu J, Haack H, Nardone J, Lee K, Reeves C, Li Y, et al. Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Cell. 2007;131(6):1190–1203. doi:10.1016/j.cell.2007.11.025.
  • Jiang X, Zhou J, Giobbie-Hurder A, Wargo J, Hodi FS. The activation of MAPK in melanoma cells resistant to BRAF inhibition promotes PD-l1 expression that is reversible by MEK and PI3K inhibition. Clin Cancer Res. 2013;19(3):598–609. doi:10.1158/1078-0432.CCR-12-2731.
  • Marzec M, Zhang Q, Goradia A, Raghunath PN, Liu X, Paessler M, Wang HY, Wysocka M, Cheng M, Ruggeri BA, et al. Oncogenic kinase npm/alk induces through stat3 expression of immunosuppressive protein cd274 (PD-l1, b7-h1). Proc Natl Acad Sci U S A. 2008;105(52):20852–20857. doi:10.1073/pnas.0810958105.
  • Awad MM, Katayama R, McTigue M, Liu W, Deng YL, Brooun A, Friboulet L, Huang D, Falk MD, Timofeevski S, et al. Acquired resistance to crizotinib from a mutation in cd74-ros1. N Engl J Med. 2013;368(25):2395–2401. doi:10.1056/NEJMoa1215530.
  • Ettinger DS, Wood DE, Aisner DL, Akerley W, Bauman J, Chirieac LR, D’Amico TA, DeCamp MM, Dilling TJ, Dobelbower M, et al. Non-small cell lung cancer, version 5.2017, nccn clinical practice guidelines in oncology. J National Compr Cancer Network. 2017;15(4):504–535.
  • Zhou J, Hu Q, Zhang X, Zheng J, Xie B, Xu Z, Zhang W. Sensitivity to chemotherapeutics of NSCLC cells with acquired resistance to EGFR-TKIs is mediated by t790m mutation or epithelial-mesenchymal transition. Oncol Rep. 2018;39(4):1783–1792. doi:10.3892/or.2018.6242.
  • Jakobsen KR, Demuth C, Sorensen BS, Nielsen AL. The role of epithelial to mesenchymal transition in resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer. Transl Lung Cancer Res. 2016;5(2):172–182. doi:10.21037/tlcr.2016.04.07.
  • Mok TSK, Wu YL, Kudaba I, Kowalski DM, Cho BC, Turna HZ, Castro G Jr., Srimuninnimit V, Laktionov KK, Bondarenko I, et al. Pembrolizumab versus chemotherapy for previously untreated, PD-l1-expressing, locally advanced or metastatic non-small-cell lung cancer (keynote-042): A randomised, open-label, controlled, phase 3 trial. Lancet. 2019;393(10183):1819–1830. doi:10.1016/s0140-6736(18)32409-7.
  • Langer CJ, Gadgeel SM, Borghaei H, Papadimitrakopoulou VA, Patnaik A, Powell SF, Gentzler RD, Martins RG, Stevenson JP, Jalal SI, et al. Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: A randomised, phase 2 cohort of the open-label keynote-021 study. Lancet Oncol. 2016;17(11):1497–1508. doi:10.1016/s1470-2045(16)30498-3.
  • Hellmann MD, Paz-Ares L, Bernabe Caro R, Zurawski B, Kim SW, Carcereny Costa E, Park K, Alexandru A, Lupinacci L, de la Mora Jimenez E, et al. Nivolumab plus ipilimumab in advanced non-small-cell lung cancer. N Engl J Med. 2019;381(21):2020–2031. doi:10.1056/NEJMoa1910231.
  • Reck M, Rodriguez-Abreu D, Robinson AG, Hui R, Csoszi T, Fulop A, Gottfried M, Peled N, Tafreshi A, Cuffe S, et al. Pembrolizumab versus chemotherapy for PD-l1-positive non-small-cell lung cancer. N Engl J Med. 2016;375(19):1823–1833. doi:10.1056/NEJMoa1606774.
  • Haratani K, Hayashi H, Tanaka T, Kaneda H, Togashi Y, Sakai K, Hayashi K, Tomida S, Chiba Y, Yonesaka K, et al. Tumor immune microenvironment and nivolumab efficacy in egfr mutation-positive non-small-cell lung cancer based on t790m status after disease progression during egfr-tki treatment. Ann Oncol. 2017;28(7):1532–1539. doi:10.1093/annonc/mdx183.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.